Project Grant R01HL175014
Award Date 8/24/25
Completion Date 6/30/30
Dollars Obligated $514K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $245,626 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University. The grant, with a project period from February 1, 2025 to January 31, 2027, will fund research to validate lipidomic signatures associated with right ventricular and pulmonary vascular dysfunction in pulmonary arterial hypertension (PAH). The project aims to replicate the researchers' preliminary findings on...
- This $193,896 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to identify clinical markers that can serve as surrogates for right ventricular-pulmonary artery (RV-PA) coupling, a metric that quantifies right ventricular adaptation in pulmonary arterial hypertension (PAH). The grantee, The Johns Hopkins University, will leverage a unique dataset of over 100 PAH patients to 1) develop a multivariable model...
- This $149,857 federal Project Grant award from the National Institutes of Health's National Institute of Environmental Health Sciences (CFDA 93.113 Environmental Health) supports research investigating how exposure to airborne particulates exacerbates pulmonary vascular remodeling in pulmonary hypertension (PH). The grant, awarded on July 7, 2025 to the University of Pittsburgh, aims to: Define population-level associations between aryl hydrocarbon receptor (AhR) agonism, plasma metabolites, and...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $586,637 to the University of New Mexico (UNM) to conduct research into the mechanisms of immune dysregulation that contribute to the development of hypoxic pulmonary hypertension (PH). The research aims to identify how chronic hypoxia causes a decrease in regulatory T cells (Tregs) and promotes the development of self-reactive T helper 17 (Th17) cells that target...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,385,536 to Rhode Island Hospital to conduct research on pulmonary arterial hypertension (PAH). The goal is to characterize endothelial cell (EC) dysfunction in PAH, with a focus on understanding the role of anoikis resistance - abnormal programmed cell death triggered by cell detachment from the vessel wall. The research will leverage a "cell...
- This federal Project Grant award of $163,145.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate sex differences in cardiac macrophages and their role in right ventricular function in pulmonary arterial hypertension (PAH). The University of Colorado-Denver, the awardee, will conduct this research with the goal of understanding how female sex hormones regulate gene expression in right ventricular macrophages and...
- This $800,962 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at Brigham & Women's Hospital on the molecular mechanisms regulating fibroproliferative pulmonary vasculopathy in early pulmonary arterial hypertension (PAH). The research aims to investigate the role of the c-terminal Src kinase (CSK) and its regulation of Src kinase activation in the context of endothelial dysfunction and fibrosis,...
- This federal Project Grant award of $522,794.00 was provided by the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), to the University of Illinois for a project titled "HV1 IN PULMONARY HYPERTENSION". The project aims to examine the role of the voltage-gated proton channel HV1 in the development and progression of pulmonary hypertension, a serious cardiovascular condition. The research will apply transgenic mouse...
- This federal Project Grant award of $596,809.00 was provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Emory University to support research on the role of the mitochondrial protein MitoNEET in pulmonary hypertension (PH). The project aims to define how MitoNEET regulates pulmonary artery smooth muscle cell mitochondrial function and proliferation, with the goal of identifying novel therapeutic targets and treatments for PH secondary to...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $658,885 to the University of Missouri System to investigate the role of the protein Response Gene to Complement 32 (RGC-32) in regulating endothelial-mesenchymal transition (EndoMT) and the development of pulmonary arterial hypertension (PAH). The research aims to determine the molecular mechanisms by which RGC-32 regulates EndoMT in...